Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Aldara (Imiquimod)
Aldara · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 250mg of Imiquimod cream application once daily 3 times per week. |
| 2 | PLACEBO_COMPARATOR | 250mg vehicle cream for application once daily 3 times per week. |
| Name | Type | Description |
|---|---|---|
| Aldara (Imiquimod) | DRUG | 250mg of Imiquimod cream for application once daily 3 times per week. |
| Vehicle cream | OTHER | 250mg vehicle cream for application once daily 3 times per week. |
Inclusion Criteria: * At least 5 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions * Free of any significant findings (e.g tattoos) in the potential application site area. * Willing to discontinue sun-tanning and use of sunbed/sun parlour use * Willing to stop use...
Aldara is used for the treatment of actinic keratosis, a skin condition involving rough, scaly lesions caused by sun damage. It is a small molecule therapy in the dermatology therapeutic area. Aldara is also known by the name imiquimod.
Aldara is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development of Aldara for actinic keratosis.
Aldara is in Phase 3 clinical development for actinic keratosis. It has been studied in one completed Phase 3 trial. As a Phase 3 asset, it remains investigational and is not approved for this indication based on the available development information.
Aldara has been evaluated in a completed Phase 3 trial, NCT00294320, titled Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions. The trial enrolled 12 participants in France, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.
Yes, Aldara is also known as imiquimod. Imiquimod is the generic or alternative name for the same small molecule therapy developed by Viatris Inc. for actinic keratosis.